Ionis Pharmaceuticals, Inc. (IONS)
Market Closed
1 Sep, 20:00
$
59. 88
-0.48
-0.7952%
$
9.95B Market Cap
- P/E Ratio
- Div Yield
1.87M Volume
-3.43 Eps
$ 60.36
Previous Close Want to track IONS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IONS closed today lower at $59.88, a decrease of -0.7952% from yesterday's close, completing a monthly increase of 13.7106% or $7.22. Over the past 12 months, IONS stock lost -25.0376%.
IONS is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0.779%. On average, the company has surpassed earnings expectations by 0.5228%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Zacks | 4 days ago
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
Zacks | 1 month ago
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Seekingalpha | 1 month ago
Ionis Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 13 | $828.79 | $708.37 | -$120.42 | -14.53% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 8,153 | $646,450 | $461,133.68 | -$185,316.32 | -28.67% |
 Tweedy Browne Tweedy, Browne Company LLC | 2.28M | $85.52M | $128.97M | $43.45M | 50.81% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $7,911 | $5,656 | -$2,255 | -28.5% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 558 | $33,616.28 | $30,924.36 | -$2,691.92 | -8.01% |
Ionis Pharmaceuticals, Inc. (IONS) FAQ
What is the stock price today?
The current price is $59.88.
On which exchange is it traded?
Ionis Pharmaceuticals, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is IONS.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 9.95B.
Has Ionis Pharmaceuticals, Inc. ever had a stock split?
No, there has never been a stock split.
Ionis Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brett Monia CEO | NASDAQ (NGS) Exchange | 462222100 CUSIP |
| US Country | 1,480 Employees | 17 Feb 2000 Last Dividend | - Last Split | 17 May 1991 IPO Date |
Overview
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of RNA-targeted therapeutics. Based in Carlsbad, California, the company has pioneered advances in drug discovery, particularly in the development of antisense therapies that modulate gene expression. Ionis Pharmaceuticals targets a wide range of diseases with a significant unmet medical need, including neurological disorders, cardiovascular diseases, and various rare diseases. Since its incorporation in 1989, Ionis has formed strategic collaborations with numerous leading biopharmaceutical companies, including Biogen, AstraZeneca, Bayer AG, GlaxoSmithKline plc, and several others, to advance its mission of delivering groundbreaking therapies to patients worldwide.
Products and Services
- SPINRAZA: A groundbreaking therapy for spinal muscular atrophy (SMA) in both pediatric and adult patients. This product demonstrates Ionis’ commitment to addressing neurological disorders with advanced RNA-targeted treatments.
- TEGSEDI: An antisense injection designed for the treatment of polyneuropathy in adults caused by hereditary transthyretin amyloidosis. This product highlights Ionis’ innovative approach to treating rare diseases through genetic modulation.
- WAYLIVRA: An antisense medicine for patients with familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy, showcasing Ionis’ capability in tackling lipid disorders.
- Eplontersen: Currently in phase 3 study, Eplontersen is being developed as a treatment for all types of ATTR (transthyretin amyloidosis) through monthly self-administered subcutaneous injections, reflecting Ionis’ progression in self-care therapeutic solutions.
- Olezarsen: In development for patients with FCS and severe hypertriglyceridemia (SHTG), Olezarsen represents Ionis’ ongoing efforts to combat severe lipid disorders.
- Donidalorsen: Aimed at patients with hereditary angioedema, this candidate signifies Ionis’ investment in developing treatments for rare hereditary disorders.
- ION363: Focused on treating patients with amyotrophic lateral sclerosis, ION363 underscores the company’s dedication to addressing debilitating neurological conditions.
- Tofersen: Aimed to inhibit the production of superoxide dismutase 1, a key factor in certain neurological diseases, demonstrating Ionis’ focus on molecular level interventions.
- Pelacarsen: Targeting established cardiovascular disease and elevated lipoprotein(a) levels, highlighting Ionis’ efforts towards cardiovascular health solutions.
- Bepirovirsen: In development to inhibit the production of viral proteins associated with hepatitis B, showcasing Ionis’ venture into antiviral therapies.
- Other notable developments include IONIS-FB-LRx, to inhibit complement factor B and address the alternative complement pathway, and ION224, aimed at reducing the production of diacylglycerol acyltransferase 2, further illustrating the breadth of Ionis’ therapeutic ambitions.
Contact Information
Address: 2855 Gazelle Court
Phone: 760 931 9200
Website: https://www.ionis.com
